has the potential to provide extended and continuous red blood cell transfusion independence; (v) that Geron is preparing to commercialize RYTELO in select EU countries in 2026, pending country-by ...

Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call ...

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

Geron Corp's imetelstat ... Imetelstat is approved for patients with lower risk MDS who have anemia (low red blood cells) and who cannot receive certain drugs designed to stimulate blood cell ...

Geron (GERN) Corporation announced that the European ... where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and ...